Ensysce Biosciences Advances CRPS Program at PainWeek 2026 Hearing

Ensysce Biosciences, a clinical-stage biotechnology company, made significant strides in advancing its Complex Regional Pain Syndrome (CRPS) program at the PainWeek 2026 conference. The company hosted a symposium attended by over 320 pain management professionals, where Dr. Jeff Gudin provided background on Ensysce’s novel program aimed at providing safer opioids for severe pain. Dr. Gudin also discussed the complexities of complex pain, specifically CRPS.

Following the conference, Ensysce was invited to participate in a Food and Drug Administration (FDA) hearing. The hearing focused on regulatory, training, and credentialing of professionals associated with the therapeutic use of psychedelic drugs, patient safety, and real-world data collection. Dr. Richard Langford, a key figure at Ensysce, contributed to the session by discussing considerations for access to psychedelic drugs and best practices for data collection and standardization.

Ensysce Biosciences is developing novel neuroplastogenic therapies that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The company is also working on a new class of highly novel opioids for the treatment of severe pain, with a focus on minimizing the risk of drug abuse and overdose.

The company's efforts to advance its CRPS program and participate in the FDA hearing reflect its commitment to addressing complex pain management challenges and ensuring patient safety. Ensysce's approach is part of a broader trend in the biotechnology sector, where companies are exploring innovative treatments for chronic pain and other conditions.

Ensysce's Phase 2 clinical trial is expected to provide valuable data on the efficacy and safety of its novel therapies. The company's work in this area is part of a larger effort to improve pain management and offer patients more effective treatment options.